Table 1.
Generalities and patient baseline of the included studies
| Author and year | Journal | Country | Patients (n) | Mean age |
|---|---|---|---|---|
| Baimukhamedov et al. 2021 [2] | Lancet Rheumatol | Kazakhstan | 1 | 67 |
| Basheikh et al. 2022 [4] | Cureus | Saudi Arabia | 1 | 43 |
| Cincinelli et al. 2021 [10] | Medicine | Italy | 1 | 27 |
| Coath et al. 2020 [11] | Rheumatology | United Kingdom | 1 | 53 |
| Danssaert et al. 2020 [13] | Cureus | USA | 1 | 37 |
| De Stefano et al. 2020 [14] | Ann Rheum Dis | Italy | 1 | 30 s |
| Di Carlo et al. 2021 [15] | Clin Exp Rheumatol | Italy | 1 | 55 |
| Fragata et al. 2020 [19] | Acta Reumatol Port | Portugal | 1 | 41 |
| Gasparotto et al. 2022 [22] | Clin Rheumatol | Italy | 1 | 60 |
| Ghauri et al. 2020 [41] | Int J Clinl Rheumatol | Pakistan | 1 | 34 |
| Gibson et al. 2020 [23] | Rheumatol Adv Pract | United Kingdom | 1 | 37 |
| Hasbani et al. 2021 [17] | Reumatismo | Libanon | 2 | 41 |
| Hønge et al. 2021 [26] | Bmj Case Reports | Denmark | 1 | 53 |
| Jali et al. 2020 [30] | Cureus | Saudi Arabia | 1 | 39 |
| Kocyigit et al. 2021 [35] | Rheumatol Int | Turkey | 1 | 53 |
| Liew et al. 2020 [37] | J Clin Rheumatol | Singapore | 1 | 47 |
| Mukarram et al. 2021 [42] | Case Rep Rheumatol | Pakistan | 5 | 39.4 |
| Ono et al. 2020 [43] | RMD Open | Japan | 1 | 50 s |
| Pal et al. 2022 [46] | Reumatol Clin | India | 23 | 42.8 |
| Parisi et al. 2020 [49] | Lancet Rheumatol | Italy | 1 | 58 |
| Saikali et al. 2021 [51] | Immun Inflamm Dis | USA | 1 | 21 |
| Saricaoglu et al. 2020 [53] | J Med Virol | Turkey | 1 | 73 |
| Schenker et al. 2020 [54] | Rheumatology | Germany | 1 | 65 |
| Shokraee et al. 2021 [57] | Trop Dis Travel Med Vaccines | Iran | 1 | 58 |
| Sureja et al. 2021 [58] | Rheumatol Adv Pract | India | 1 | 27 |
| Waller et al. 2020 [61] | Rheumatol Adv Pract | United Kingdom | 1 | 16 |
| Yokogawa et al. 2020 [63] | Ann Rheum Dis | Japan | 1 | 57 |
RCT—Randomised controlled trial